Defective endogenous opioid response to exercise in type I diabetic patients

Metabolism: Clinical and Experimental
T WankeK Irsigler

Abstract

Plasma beta-endorphin (beta-E) concentration was determined before, during, and after a standardized incremental exercise test to maximal capacity in eight type I diabetic patients and eight normal control subjects. Diabetic patients were studied under normoglycemic and hyperglycemic conditions in a single-blind random fashion to differentiate between the effects of acute hyperglycemia and of diabetes per se on the beta-E response to exercise. The perceived magnitude of leg effort elicited by exercise was evaluated using a category scale. Whereas plasma beta-E concentrations increased in control subjects with increasing workload, causing significantly higher beta-E levels at the end of exercise than at the beginning (P < .001), no such increase could be observed in the diabetic patients under normoglycemic and hyperglycemic conditions. In addition, baseline plasma beta-E concentrations were significantly lower in normoglycemic (P < .01) and hyperglycemic (P < .001) diabetic patients than in control subjects. Even during the recovery period, patients' beta-E levels remained significantly lower than those of control subjects. At submaximal levels of power output, the perceived intensity of leg effort was significantly higher in n...Continue Reading

References

May 1, 1992·Diabetes·A L McCall
Jun 1, 1992·The American Review of Respiratory Disease·K J KillianE J Campbell
Apr 1, 1988·Journal of the American College of Cardiology·C FalconeC Montemartini
Sep 1, 1988·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·L J FormanP Vasilenko
Sep 3, 1981·The New England Journal of Medicine·O Appenzeller
Aug 1, 1982·The Journal of Clinical Endocrinology and Metabolism·R H GernerD H Catlin
Feb 1, 1983·Clinical Endocrinology·C MorettiG M Besser

❮ Previous
Next ❯

Citations

Aug 26, 1998·Pharmacology, Biochemistry, and Behavior·R B KanarekK E D'Anci
Jan 1, 1997·Peptides·G A OlsonA J Kastin
Dec 16, 2011·The Journal of Clinical Endocrinology and Metabolism·Sofiya MilmanIlan Gabriely
May 15, 2015·Scandinavian Cardiovascular Journal : SCJ·Thomas BirkelundHanne Berg Ravn
Sep 17, 2009·Pediatric Diabetes·Kenneth RobertsonMichael C Riddell
Oct 3, 2008·Pediatric Diabetes·Jaime S Rosa, Pietro R Galassetti
Jan 24, 2008·Pediatric Diabetes·Kenneth RobertsonRagnar Hanas
Dec 19, 2014·British Journal of Pharmacology·John P HeadrickJason N Peart
Aug 30, 2000·Oncogene·S PanigoneD Delia
Aug 25, 2021·International Immunopharmacology·Hai HuangFengping Shan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.